Suppression of Luteinizing Hormone Enhances HSC Recovery after Hematopoietic Injuries
Enrico Velardi(Bambino Gesù Children's Hospital), Jarrod A. Dudakov(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Tobias Wertheimer(Memorial Sloan Kettering Cancer Center), Yusuke Shono(Memorial Sloan Kettering Cancer Center), Robert R. Jenq(City Of Hope National Medical Center), Jennifer J. Tsai(Memorial Sloan Kettering Cancer Center), Fabiana M. Kreines(Memorial Sloan Kettering Cancer Center), Sophie Lieberman(Memorial Sloan Kettering Cancer Center), Jae-Hung Shieh(Cornell University), Kimon V. Argyropoulos(Memorial Sloan Kettering Cancer Center), Lauren Young(Memorial Sloan Kettering Cancer Center), Alan M. Hanash(Memorial Sloan Kettering Cancer Center), Malcolm A.S. Moore(Memorial Sloan Kettering Cancer Center), Marcel R.M. van den Brink(City Of Hope National Medical Center)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid Cells
|Science|1986|1.2k
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937